Welcome to our dedicated page for Magnera SEC filings (Ticker: MAGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Magnera's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Magnera's regulatory disclosures and financial reporting.
Magnera Corporation is asking shareholders to vote at its 2026 virtual annual meeting on electing nine directors, ratifying Ernst & Young as auditor, and approving 2025 executive pay. The meeting will be held online on March 9, 2026, for holders of common stock as of December 31, 2025. Magnera reports 2025 revenue of $3,204M, reported operating income of $5M, annualized EBITDA of $362M, and post‑merger free cash flow of $126M. CEO Curtis Begle’s 2025 target total direct compensation is $6.6M, heavily weighted to performance-based incentives and equity. The board highlights strong governance features, including an independent chair, majority voting in uncontested elections, proxy access, and robust risk and corporate responsibility oversight.
Magnera Corporation announced that it expects to hold its annual meeting of shareholders on March 9, 2026. This meeting is where shareholders vote on directors and other key corporate matters. The company also set clear deadlines for shareholders who want to influence the agenda.
Shareholders seeking to include a proposal in the company’s proxy statement under SEC Rule 14a-8 must submit it in writing to the corporate secretary by December 9, 2025, which the company considers a reasonable time before it expects to print and send proxy materials. Shareholders who want to bring director nominations or other proposals outside of Rule 14a-8 must also deliver proper written notice under the company’s Amended and Restated Bylaws by December 9, 2025, which is 90 days before the scheduled meeting date.
Magnera Corporation reports its first full year as a combined company after merging with Glatfelter, generating $3,204 million in net sales, up 47% from $2,187 million in 2024. Operating income improved to $5 million from a loss of $141 million, but higher interest on new debt led to a net loss of $159 million, similar to the prior year’s $154 million loss. The Americas segment produced $1,833 million of net sales and $241 million of adjusted EBITDA, while Rest of World delivered $1,371 million of net sales and $113 million of adjusted EBITDA. The GLT transaction added $1,145 million of 2025 revenue and increased goodwill to $663 million.
To fund the deal and a distribution to Berry, Magnera closed a $731 million term loan and issued $1,300 million of senior secured notes, ending 2025 with $1,952 million of long-term debt and $305 million of cash. Free cash flow was $126 million in 2025, and the company projects 2026 cash from operations of $170–$190 million and free cash flow of $90–$110 million on planned capital spending of $80 million. An internal control audit identified material weaknesses related to the merger purchase price allocation, certain legacy IT general controls, and deferred tax assets, resulting in an adverse opinion on internal control over financial reporting, although the financial statements received an unqualified opinion.
Magnera Corporation filed a Form 8-K to announce that it has reported its results of operations for the year ended September 27, 2025. The company states that these results are described in a press release dated November 19, 2025, which is furnished as Exhibit 99.1.
The common stock of Magnera trades on the New York Stock Exchange under the symbol MAGN. The company notes that the information in this report and Exhibit 99.1 is being furnished, not filed, which affects how it is treated under federal securities laws.
Magnera Corp (MAGN) reported that director Bruce Brown received a grant of 5,871 restricted stock units (RSUs) on 11/14/2025. The RSUs were granted at a price of $0 and represent a prorated portion of the company’s Annual Director Award for the period between the 2024 RSU lapse reported on November 4, 2025 and the 2026 Annual Shareholder Meeting.
The filing explains that this 2025 prorated director award will vest in full one year from the grant date, on 11/14/2026. The RSUs have no value until all restrictions lapse on the final vesting date. Following this grant, Brown beneficially owns 5,871 derivative securities in the form of RSUs, held directly.
Magnera Corp reported a director equity grant on a Form 4 for board member Kevin Fogarty. On 11/14/2025, the director received 5,871 restricted stock units (RSUs) tied to Magnera common stock at a stated price of $0 per unit. The award is described as a 2025 Prorated Director Award, intended to align the director equity schedule with the timing of the Annual Shareholder Meeting. According to the filing, these RSUs have no value until all restrictions lapse, and this prorated grant is for the period between the 2024 RSU lapse reported on November 4, 2025 and the 2026 Annual Shareholder Meeting. The RSUs vest in full one year from the grant date, on 11/14/2026, and are held as direct ownership by the reporting person.
Magnera Corp director Michael Curless reported an equity grant on Form 4. On 11/14/2025 he received 5,871 restricted stock units (RSUs), each representing one share of Magnera common stock with a stated price of $0 for the derivative security. The award is described as a 2025 prorated director grant intended to align the director equity schedule with the company’s Annual Shareholder Meeting cycle.
These 5,871 RSUs are scheduled to vest in full one year from the grant date, on 11/14/2026, at which time the restrictions lapse and the units convert into common shares. Following this grant, Curless is shown as directly owning 5,871 derivative securities tied to Magnera common stock.
Magnera Corp reported a stock-based award to one of its directors, Thomas Fahnemann. On 11/14/2025, he received 5,871 restricted stock units (RSUs) of Magnera common stock at an exercise price of $0, reported as directly owned. The filing explains that this 2025 prorated director award is intended to align the director equity schedule with the company’s Annual Shareholders Meeting. The grant represents a prorated portion of the Annual Director Award covering the period between the 2024 RSU lapse reported on November 4, 2025 and the 2026 Annual Shareholder Meeting. The RSUs vest in full one year from the grant date, on 11/14/2026, at which time the restrictions lapse and the units can deliver value as shares of common stock.
Magnera Corp (MAGN) reported a Form 4 insider transaction for director Thomas Salmon involving a new grant of derivative securities in the form of restricted stock units (RSUs). On 11/14/2025, the director received 5,871 RSUs with an exercise price of $0, reflecting equity compensation rather than a cash purchase. These RSUs relate to Magnera common stock with par value $0.01 per share and vest in full one year from the grant date, on 11/14/2026. The company notes that RSUs have no value until all restrictions lapse on the final vesting date and explains that this 2025 prorated director award is intended to align the director equity schedule with the timing of the Annual Shareholder Meeting in 2026.